6CPS
| |
6VEO
| ATAD2B bromodomain in complex with 4-({[(3R,4R)-4-{[3-methyl-5-(5-methylpyridin-3-yl)-2-oxo-1,2-dihydro-1,7-naphthyridin-8-yl]amino}piperidin-3-yl]oxy}methyl)-1lambda~6~-thiane-1,1-dione (compound 38) | Descriptor: | 4-({[(3R,4R)-4-{[3-methyl-5-(5-methylpyridin-3-yl)-2-oxo-1,2-dihydro-1,7-naphthyridin-8-yl]amino}piperidin-3-yl]oxy}methyl)-1lambda~6~-thiane-1,1-dione, ATPase family AAA domain-containing protein 2B, SULFATE ION | Authors: | Glass, K.C. | Deposit date: | 2020-01-02 | Release date: | 2020-10-28 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (2.4 Å) | Cite: | Structural Insights into the Recognition of Mono- and Diacetylated Histones by the ATAD2B Bromodomain. J.Med.Chem., 63, 2020
|
|
7M97
| |
8UHL
| ATAD2B bromodomain in complex with histone H4 acetylated at lysine 12 | Descriptor: | ATPase family AAA domain-containing protein 2B, Histone H4 | Authors: | Phillips, M, Montgomery, C, Nix, J.C, Glass, K.C. | Deposit date: | 2023-10-09 | Release date: | 2024-06-05 | Method: | X-RAY DIFFRACTION (1.92 Å) | Cite: | Impact of Combinatorial Histone Modifications on Acetyllysine Recognition by the ATAD2 and ATAD2B Bromodomains. J.Med.Chem., 67, 2024
|
|
8UK5
| Crystal structure of the bromodomain of human ATAD2B in complex with histone H4S1(ph)K5ac | Descriptor: | ATPase family AAA domain-containing protein 2B, Histone H4S1(ph)K5ac | Authors: | Montgomery, C, Phillips, M, Nix, J.C, Glass, K.C. | Deposit date: | 2023-10-12 | Release date: | 2024-06-05 | Method: | X-RAY DIFFRACTION (1.4 Å) | Cite: | Impact of Combinatorial Histone Modifications on Acetyllysine Recognition by the ATAD2 and ATAD2B Bromodomains. J.Med.Chem., 67, 2024
|
|
8SDQ
| |
8SDO
| |
8SDX
| ATAD2B bromodomain in complex with histone H4 acetylated at lysine 5 with Serine 1 mutation to Cysteine | Descriptor: | ATPase family AAA domain-containing protein 2B, SULFATE ION, histone H4S1CK5ac | Authors: | Phillips, M, Montgomery, C, Nix, J.C, Glass, K.C. | Deposit date: | 2023-04-07 | Release date: | 2024-06-05 | Method: | X-RAY DIFFRACTION (2.69 Å) | Cite: | Impact of Combinatorial Histone Modifications on Acetyllysine Recognition by the ATAD2 and ATAD2B Bromodomains. J.Med.Chem., 67, 2024
|
|
4QYL
| |
4QYD
| |
3MDF
| Crystal structure of the RRM domain of Cyclophilin 33 | Descriptor: | Peptidyl-prolyl cis-trans isomerase E | Authors: | Hom, R.A, Chang, P.Y, Roy, S, Mussleman, C.A, Glass, K.C, Seleznevia, A.I, Gozani, O, Ismagilov, R.F, Cleary, M.L, Kutateladze, T.G. | Deposit date: | 2010-03-30 | Release date: | 2010-05-12 | Last modified: | 2023-09-06 | Method: | X-RAY DIFFRACTION (1.85 Å) | Cite: | Molecular mechanism of MLL PHD3 and RNA recognition by the Cyp33 RRM domain. J.Mol.Biol., 400, 2010
|
|
7M98
| ATAD2 bromodomain complexed with histone H4K5ac (res 1-10) ligand | Descriptor: | ATPase family AAA domain-containing protein 2, Histone H4 | Authors: | Malone, K.L, Phillips, M, Nix, J.C, Glass, K.C. | Deposit date: | 2021-03-30 | Release date: | 2021-09-22 | Last modified: | 2023-11-15 | Method: | X-RAY DIFFRACTION (1.6 Å) | Cite: | Coordination of Di-Acetylated Histone Ligands by the ATAD2 Bromodomain. Int J Mol Sci, 22, 2021
|
|
8VX0
| CRYSTAL STRUCTURE OF CYP2C9*14 IN COMPLEX WITH LOSARTAN | Descriptor: | Cytochrome P450 2C9, PHOSPHATE ION, POTASSIUM ION, ... | Authors: | Shah, M.B. | Deposit date: | 2024-02-02 | Release date: | 2024-06-12 | Last modified: | 2024-06-26 | Method: | X-RAY DIFFRACTION (3.05 Å) | Cite: | Structural and biophysical analysis of cytochrome P450 2C9*14 and *27 variants in complex with losartan. J.Inorg.Biochem., 258, 2024
|
|
8VZ7
| |
6VLT
| Crystal Structure of Human P450 2C9*2 Genetic Variant in Complex with Losartan | Descriptor: | 5-CYCLOHEXYL-1-PENTYL-BETA-D-MALTOSIDE, Cytochrome P450 2C9, PROTOPORPHYRIN IX CONTAINING FE, ... | Authors: | Shah, M.B. | Deposit date: | 2020-01-25 | Release date: | 2020-09-30 | Last modified: | 2024-04-03 | Method: | X-RAY DIFFRACTION (3.12 Å) | Cite: | Structure of Cytochrome P450 2C9*2 in Complex with Losartan: Insights into the Effect of Genetic Polymorphism. Mol.Pharmacol., 98, 2020
|
|
3LH0
| |
3LGF
| |
3LGL
| |
7RL2
| |